Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
17
01
2022
received:
03
10
2021
accepted:
17
01
2022
pubmed:
7
4
2022
medline:
7
7
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
To correlate the North Star Ambulatory Assessment (NSAA) and timed rise from floor (TRF) recorded at age of expected peak with age at loss of ambulation (LOA) in Duchenne muscular dystrophy (DMD). Male children with DMD enrolled in the UK North Start Network database were included according to the following criteria: follow-up longer than 3 years, one NSAA record between 6 years and 7 years 6 months (baseline), at least one visit when older than 8 years. Data about corticosteroid treatment, LOA, genotype, NSAA, and TRF were analysed. Age at LOA among the different groups based on NSAA and TRF was determined by log-rank tests. Cox proportional hazard models were used for multivariable analysis. A total of 293 patients from 13 different centres were included. Mean (SD) age at first and last visit was 5 years 6 months (1 year 2 months) and 12 years 8 months (2 years 11 months) (median follow-up 7 years 4 months). Higher NSAA and lower TRF at baseline were associated with older age at LOA (p<0.001). Patients scoring NSAA 32 to 34 had a probability of 0.61 of being ambulant when older than 13 years compared with 0.34 for those scoring 26 to 31. In multivariable analysis, NSAA, TRF, and corticosteroid daily regimen (vs intermittent) were all independently associated with outcome (p=0.01). Higher functional abilities at peak are associated with older age at LOA in DMD. This information is important for counselling families. These baseline measures should also be considered when designing clinical trials.
Identifiants
pubmed: 35385138
doi: 10.1111/dmcn.15176
pmc: PMC9303180
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
979-988Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Investigateurs
Sandya Tirupath
(S)
Melanie Douglas
(M)
Jaci McFetridge
(J)
Deepak Parasuraman
(D)
Zoya Alhaswani
(Z)
Heather McMurchie
(H)
Rosanna Rabb
(R)
Anirban Majumdar
(A)
Kayal Vijayakumar
(K)
Sam Amin
(S)
Faye Mason
(F)
Claire Frimpong-Ansah
(C)
Frances Gibbon
(F)
Bethan Parson
(B)
Karen Naismith
(K)
Julie Burslem
(J)
Alex Baxter
(A)
Clare Eadie
(C)
Iain Horrocks
(I)
Marina Di Marco
(M)
Anne-Marie Childs
(AM)
Lindsey Pallant
(L)
Stefan Spinty
(S)
Alison Shillington
(A)
Sarah Gregson
(S)
Laura Cheshman
(L)
Elizabeth Wraige
(E)
Vasantha Gowda
(V)
Heinz Jungbluth
(H)
Jennie Sheehan
(J)
Imelda Hughes
(I)
Sinead Warner
(S)
Volker Straub
(V)
Michela Guglieri
(M)
Anna Mayhew
(A)
Gabby Chow
(G)
Sarah Williamson
(S)
Tracey Willis
(T)
Richa Kulshrestha
(R)
Nicholas Emery
(N)
Sithara Ramdas
(S)
Hayley Ramjattan
(H)
Christian de Goede
(C)
Andrea Selley
(A)
Min Ong
(M)
Kay White
(K)
Marjorie Illingworth
(M)
Michelle Geary
(M)
Jenni Palmer
(J)
Cathy White
(C)
Kate Greenfield
(K)
Gemunu Hewawitharana
(G)
Yvonne Julien
(Y)
Elma Stephens
(E)
Jane Tewnion
(J)
Gautam Ambegaonkar
(G)
Deepa Krishnakumar
(D)
Jacqui Taylor
(J)
Catherine Ward
(C)
Tracey Willis
(T)
Elizabeth Wright
(E)
Claire Rylance
(C)
Informations de copyright
© 2022 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
Références
Ther Clin Risk Manag. 2015 Sep 28;11:1475-88
pubmed: 26451113
Lancet. 2018 Feb 3;391(10119):451-461
pubmed: 29174484
Nat Rev Dis Primers. 2021 Feb 18;7(1):13
pubmed: 33602943
Dev Med Child Neurol. 2011 Jun;53(6):535-42
pubmed: 21410696
J Neuromuscul Dis. 2015 Sep 2;2(3):269-279
pubmed: 27858743
Neurology. 2011 Jul 19;77(3):250-6
pubmed: 21734183
Neurology. 2015 Sep 22;85(12):1048-55
pubmed: 26311750
J Clin Invest. 2017 Jun 1;127(6):2418-2432
pubmed: 28481224
Muscle Nerve. 2013 Jul;48(1):55-67
pubmed: 23649481
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):698-705
pubmed: 23250964
Neuromuscul Disord. 1991;1(1):19-29
pubmed: 1822774
JAMA Neurol. 2020 Sep 1;77(9):1122-1131
pubmed: 32539076
Neuromuscul Disord. 2016 Sep;26(9):576-83
pubmed: 27423700
Neurology. 2016 Jul 26;87(4):401-9
pubmed: 27343068
Neurology. 2020 Sep 8;95(10):e1381-e1391
pubmed: 32611643
Lancet. 2015 May 2;385(9979):1748-1757
pubmed: 25907158
Ann Neurol. 2012 Mar;71(3):304-13
pubmed: 22451200
PLoS One. 2019 Sep 3;14(9):e0221097
pubmed: 31479456
PLoS One. 2014 Oct 01;9(10):e108205
pubmed: 25271887
PLoS One. 2016 Oct 13;11(10):e0164684
pubmed: 27737016
PLoS One. 2013;8(1):e52512
pubmed: 23326337
Muscle Nerve. 2013 Sep;48(3):343-56
pubmed: 23681930
PLoS One. 2016 Aug 05;11(8):e0160195
pubmed: 27494024
Pediatr Neurol. 2020 Dec;113:15-20
pubmed: 32979653
Orphanet J Rare Dis. 2020 Jun 5;15(1):141
pubmed: 32503598
PLoS One. 2016 Mar 16;11(3):e0151445
pubmed: 26982196
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):149-55
pubmed: 25733532
PLoS One. 2019 Jun 25;14(6):e0218683
pubmed: 31237898
PLoS One. 2020 Jun 18;15(6):e0232870
pubmed: 32555695
Dev Med Child Neurol. 2022 Aug;64(8):979-988
pubmed: 35385138
Physiother Res Int. 2012 Jun;17(2):101-9
pubmed: 21954141